We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Systemically administered liposome-encapsulated Ad-PEDF potentiates the anti-cancer effects in mouse lung metastasis melanoma.
- Authors
Shi, Hua-Shan; Yang, Li-Ping; Wei, Wei; Su, Xiao-Qing; Li, Xiao-Peng; Li, Meng; Luo, Shun-Tao; Zhang, Hai-Long; Lu, Lian; Mao, Yong-Qiu; Kan, Bing; Yang, Li
- Abstract
<bold>Background: </bold>The use of adenoviral vector for gene therapy is still an important strategy for advanced cancers, however, the lack of the requisite coxsackie-adenovirus receptor in cancer cells and host immune response to adenovirus limit the application of adenoviral vector in vivo.<bold>Method: </bold>We designed the antiangiogenic gene therapy with recombinant PEDF adenovirus (Ad-PEDF) encapsulated in cationic liposome (Ad-PEDF/Liposome), and investigated the anti-tumor efficacy of Ad-PEDF/Liposome complex on inhibition of tumor metastasis.<bold>Results: </bold>We found that systemic administration of Ad-PEDF/liposome was well tolerated and resulted in marked suppression of tumor growth, and was more potent than uncoated Ad-PEDF to induce apoptosis in B16-F10 melanoma cells and inhibit murine pulmonary metastases in vivo. After Ad-luciferase was encapsulated with liposome, its distribution decreased in liver and increased in lung. The anti-Ad IgG level of Ad-PEDF/Liposome was significantly lower than Ad-PEDF used alone.<bold>Conclusion: </bold>The present findings provide evidences of systematic administration of cationic liposome-encapsulated Ad-PEDF in pulmonary metastatic melanoma mice model, and show an encouraging therapeutic effect for further exploration and application of more complexes based on liposome-encapsulated adenovirus for more cancers.
- Publication
Journal of Translational Medicine, 2013, Vol 11, Issue 1, p86
- ISSN
1479-5876
- Publication type
journal article
- DOI
10.1186/1479-5876-11-86